I talked to an analyst and it is of my opinion that the stock recent trading range is purely some of the holders of the warrents who are free to exercise now. Most were hedged, but the boorrow is so expensive some choose to exercise and sell. Also, Allergan/Levadex is 9-12 months behind now after the CRL so the story got better for partnership or takeout negotiations. Analyst opinion 12-15 takeout
6-8 partner. Patent protection last week also added to long term value. Dec option are cheap they trade on a 60 vol with the puts over 100 because of the borrow.